Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary - Primary - GI - N0147
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials An, Ming-Wen , Tang, Jun , Grothey, Axel , Sargent, Daniel J. ... - - Contemp Clin Trials Commun - 2019 Manuscript - Secondary-not-in-original - Primary - GI - A151817 , N0026 , N9741 , NCCTG-N9741
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-9741
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - GI - N0148
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online Gill, Sharlene , Loprinzi, Charles , Kennecke, Hagen , Grothey, Axel ... - - Cancer - 2011 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - NCCTG-89-46-51 , NCCTG-914653
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey, Axel , Hedrick, Eric E , Mass, Robert D , Sarkar, Somnath ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original - Primary - GI - N9741
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Grothey, Axel , Nikcevich, Daniel A. , Sloan, Jeff A. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - Symptom Inter - N04C7
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 Heun, James M. , Grothey, Axel , Branda, Megan E. ... - - Oncologist - 2011 Manuscript - Secondary - Primary - GI - NCCTG-N9741
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients Liu, Heshan , Tan, Angelina D. , Qin, Rui , Sargent, Daniel J. ... - - SOJ Anesthesiol Pain Manag - 2015 Manuscript - Primary - Primary - Health Outcome - N0897
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance) Loprinzi, Charles L. , Qin, Rui , Dakhil, Shaker R. ... - - J. Clin. Oncol - 2014 Manuscript - Primary - Primary - Symptom Inter - N08CB
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance) Major-Elechi, Brittny T. , Novotny, Paul J. , Singh, Jasvinder A. ... - - Int J Stat Med Res - 2018 Manuscript - No-Endpoint - Other - Health Outcome - NCCTG-89-20-52
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (Alliance) McCleary, Nadine J , Hubbard, Joleen , Mahoney, Michelle R ... - - J Geriatr Oncol - 2018 Manuscript - Primary - Primary - GI - N0949
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741 McLeod, Howard L. , Sargent, Daniel J. , Marsh, Sharon ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - PPP - N9741
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702 Meyerhardt, Jeffrey A. , Shi, Qian , Fuchs, Charles S. ... - ASCO - JCO - 2020 Abstract - Primary - Primary - GI - CALGB-80702
Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance) Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary - Primary - Symptom Inter - N08CB
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance) Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. , Smith, Ellen M.L. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary - Primary - Symptom Inter - N08CB
Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505) Pachman, Deirdre R. , Qin, Rui , Seisler, Drew ... - - Support Care Cancer - 2016 Manuscript - Primary - Primary - Symptom Inter - A151505 , N08C1 , N08CB
A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance) Ruddy, Kathryn Jean , Pachman, Dierdre , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - Symptom Inter - A151505 , N08C1 , N08CB
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer Sargent, Daniel J. , Köhne, Claus Henning , Sanoff, Hanna Kelly ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer Sargent, Daniel J. , Marsoni, Silvia , Monges, Genevieve ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - GI - N994C
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. Sargent, Daniel J , Patiyil, Smitha , Yothers, Greg ... - - J. Clin. Oncol. - 2007 Manuscript - No-Endpoint - Other - GI - ACCENT
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. Schrag, Deborah , Dueck, Amylou C. , Naughton, Michelle Joy ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Health Outcome - CALGB-70502 , CALGB-80405
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database Shi, Qian , Andre, Thierry , Grothey, Axel , Yothers, Greg ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - CALGB-89803 , NCCTG-784852 , NCCTG-874651 , NCCTG-894651 , NCCTG-914653
Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance) Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - N0147
Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy. Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - Symptom Inter - NCCTG-89-20-52
A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance) Thanarajasingam, Gita , Atherton, Pamela J. , Novotny, Paul J. ... - - Lancet Oncol. - 2016 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N9741 , NCCTG-97-92-54
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance) Xie, Hao , Lafky, Jacqueline M. , Morlan, Bruce W. ... - - Ther Adv Med Oncol - 2020 Manuscript - Primary - Primary - GI - N054C
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer Yuan, Chen , Renfro, Lindsay , Ambadwar, Pratibha B. , Ou, Fang-Shu ... - - Cancer Causes Control - 2019 Manuscript - Secondary-not-in-original - Primary - PPP - N9741
Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial. Zimmerman, Collin Thomas , Atherton, Pamela J. , Pachman, Deirdre R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - Symptom Inter - NCT01611155
Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial Zimmerman, Collin , Atherton, Pam , Pachman, Deirdre , Seisler, Drew ... - MASCC / ISOO - Support Care Cancer - 2015 Abstract - Primary - Primary - Symptom Inter - NCT01611155
MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy Zimmerman, Collin , Atherton, Pamela J. , Pachman, Deirdre ... - - Support Care Cancer - 2016 Manuscript - Primary - Primary - Symptom Inter - NCT01611155
Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set de Gramont, Aimery , Hubbard, Joleen , Shi, Qian ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - GI - N9741
